Related Experiment Videos
[Clofibrate therapy--the status quo]
Insights
Clofibrate, containing clofibric acid, is a long-standing, effective lipid-lowering drug that reduces cardiovascular risks. While beneficial for triglyceride and cholesterol metabolism, it may increase the risk of gallstones.
Area of Science:
- Pharmacology
- Metabolic Medicine
- Cardiovascular Research
Context:
- Clofibrate is a well-established lipid-lowering medication.
- It significantly impacts triglyceride and cholesterol metabolism.
- Its efficacy in reducing cardiovascular events is supported by follow-up studies.
Purpose:
- To detail the role of clofibric acid as the active component of clofibrate.
- To outline clofibrate's metabolic effects and clinical applications.
- To highlight potential side effects and specific indications for its use.
Summary:
- Clofibrate, with clofibric acid as its active substance, is a highly effective and long-used lipid-decreasing agent.
- It influences both triglyceride and cholesterol metabolism, demonstrably reducing coronary morbidity and mortality.
- A potential side effect is an increased incidence of gallstones, with specific indications for hypertriglyceridemia and refractory hypercholesterolemia.
Impact:
- Provides a comprehensive overview of clofibrate's therapeutic profile.
- Informs clinical decisions regarding its use in managing dyslipidemias.
- Contributes to understanding the risk-benefit balance of clofibrate therapy.
Abstract:
Clofibrinic acid (Regadrin) is the effective substance of clofibrate. Clofibrate is one of the lipid-decreasing medicaments; which are used for the longest time and which are most effective. It has an influence above all on the metabolism of triglycerides, but also on the metabolism of cholesterol. The reduction of coronary morbidity and mortality by clofibrate was proved in a number of follow-up studies. An increased incidence of cholelithiasis may be a side-effect of the clofibrate therapy. Prefered indications for clofibrate are hypertriglyceridaemias in HLP type IIb, III, IV and V an (in combination with other drugs) therapy-refractery hypercholesterolaemias in HLP type IIa and IIb.